Position in ACLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$24,398,675
+$24,107,473 QoQ
Shares Held
212,495
+2518.2% QoQ
Ownership
0.363%
of shares outstanding
% of Portfolio
0.37%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LMR Partners LLP holds $224,816,570 across 60 Biotechnology names. ACLX ranks #2 (10.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
74,661 | $24,703,084 | |
| 2 | ACLX |
Arcellx, Inc.
This page
|
212,495 | $24,398,675 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
400,000 | $21,088,000 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
324,939 | $18,355,804 | |
| 5 | ARGX |
Argenx SE
|
23,488 | $17,152,112 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
|
403,622 | $16,237,713 | |
| 7 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,049,700 | $15,178,662 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
130,000 | $12,642,500 |
All Filings in ACLX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $24,398,675 | 212,495 | Shares | Other | 2026-05-15 | |
| 2023-09-30 | $291,202 | 8,116 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $256,627 | 8,116 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $314,508 | 10,208 | Shares | Sole | 2023-05-15 | |
| 2022-06-30 | $255,705 | 14,143 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $243,990 | 17,403 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||